M42's Emirati Genome Programme Has Become The Gulf's Most Important Healthcare AI Story, And Oracle Health Is The Quiet Catalyst

M42's Emirati Genome Programme Has Become The Gulf's Most Important Healthcare AI Story, And Oracle Health Is The Quiet Catalyst

Abu Dhabi-headquartered M42 is quietly running the most ambitious population-genomics AI programme outside the UK Biobank and the US All of Us cohort. The group now operates more than 480 facilities across 27 countries, combining direct patient care with advanced capabilities in genomics, digital platforms, and clinical research. The flagship is the Emirati Genome Programme, led by the Abu Dhabi Department of Health and delivered through M42's integrated clinical-genomic infrastructure. What has changed in 2025-2026 is the partnership with Oracle Health, which has pulled genomic data directly into electronic health records, enabling pharmacogenomic recommendations at the point of care.

That is the moment population genomics shifts from a research programme to operational medicine.

Dimitris Moulavasilis, M42's Group Chief Executive, describes the model as operating at three interconnected levels simultaneously: patient care, population health, and system infrastructure. That is less corporate-speak than it sounds. Most health systems operate at one level well and the other two poorly. M42 is one of a small number of global operators attempting to stitch all three together into a single integrated AI-enabled care pathway.

Why The Genome Programme Has Become A National Asset

The Emirati Genome Programme has already expanded premarital screening to include testing for approximately 570 genes associated with more than 840 inherited disorders. That scale lets couples understand shared genetic risks before starting a family and access IVF treatment where appropriate. In Abu Dhabi specifically, expanded newborn screening now uses genomic tools to identify treatable inherited conditions at birth, allowing clinical intervention before symptoms develop. Both programmes reduce lifetime health costs and improve outcomes, and both generate the longitudinal data that trains the AI models M42 uses for clinical decision support.

That virtuous loop is the whole point. The richer the population genomic dataset, the better M42's AI models can stratify risk, recommend prescribing, and flag rare conditions. The better the AI, the stronger the clinical outcomes. The stronger the outcomes, the more political and financial support the programme attracts.

That is why the Abu Dhabi Department of Health has committed to scaling the programme and integrating it with the emirate's broader AI-native government push by 2027.

The Oracle Health Partnership Is The Operational Piece

The integration of genomic data into electronic health records via Oracle Health is the piece that turns research into practice. Dr Fahed Al Marzooqi, CEO of M42's Integrated Health Solutions platform, framed it plainly: "Being able to inform the physician at the point of prescribing regarding the level of genetic compatibility a patient has with a certain drug will increase the likelihood that the most appropriate medication is given."

That is pharmacogenomics in practice. A cardiologist at Cleveland Clinic Abu Dhabi or Sheikh Shakhbout Medical City pulls up a patient record and sees genetic markers that guide drug selection and dosing. Instead of trial-and-error with statins, SSRIs, or anticoagulants, the system flags the genetic compatibility data from the Emirati Genome Programme automatically. That is production-grade precision medicine, delivered in clinical workflow rather than in a research paper.

We operate simultaneously at three interconnected levels: patient care, population health, and system infrastructure. That integration is what makes the AI work.

Being able to inform the physician at the point of prescribing regarding the level of genetic compatibility a patient has with a certain drug will increase the likelihood that the most appropriate medication is given.

How This Compares To Other MENA Health AI Programmes

Multiple regional programmes are now running parallel plays. Jordan's King Hussein Cancer Center has rolled out AI radiology across Amman. Qatar's Sidra Medicine has partnered with Vitafluence for paediatric AI. Saudi Arabia's Sehhaty app is the kingdom's flagship consumer-facing digital health tool.

Each of these is solid. None matches M42's scale across facilities, countries, and genomic data integration.

The Illumina Pipeline Is The Under-Reported Detail

M42's sequencing volume runs largely on Illumina platforms, with clinical-grade turnaround times now under a week for most panels. That sequencing infrastructure, combined with automated variant-interpretation pipelines, is what makes the Emirati Genome Programme's 570-gene screening viable at population scale. Without the sequencing throughput, the AI has no data. Without the AI, the data has no clinical leverage.

M42 has invested heavily in both sides of that loop.

The programme is also comparable to the UK Biobank and 100,000 Genomes Project in methodology, though its demographic focus on Emirati and broader MENA populations gives it a distinct scientific value. Most global genomic reference datasets are skewed toward European ancestry. M42's dataset is one of the most comprehensive for Gulf-specific variants, which raises its clinical utility for the region sharply.